Curis Announces Presentations Related to CUDC-907 and Erivedge® at 2016 ASCO Annual Meeting

On June 02, 2016 Curis, Inc. (Nasdaq:CRIS), a biotechnology company focused on the development and commercialization of innovative and effective therapeutics for the treatment of cancer, reported that a Phase 2 trials-in-progress poster for CUDC-907, Curis’ proprietary drug candidate in development for treatment of patients with relapsed refractory diffuse large B-cell lymphoma (DLBCL) with MYC gene alterations, will be presented at the 2016 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting to be held from June 3-7 in Chicago, IL (Press release, Curis, JUN 2, 2016, View Source [SID:1234512953]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, data will be presented from clinical studies of Erivedge, a first-in-class drug approved for the treatment of patients with advanced basal cell carcinoma (BCC). Roche and Genentech, a member of the Roche Group, develop and commercialize Erivedge under a collaboration agreement with Curis.

Additional information on the presentations can be found below and abstracts can be accessed at www.asco.org.

CUDC-907 Poster Presentation:

Date/Time: Monday, June 6, 8 AM — 11:30 AM CDT
Abstract Number: TPS7579
Presentation Title: Phase 2, open-label study of CUDC-907 with and without rituximab
in patients with relapsed/refractory MYC-altered diffuse large B cell
lymphoma

Erivedge Poster Presentations:

Date/Time: Poster Session: Saturday, June 4, 1 PM — 4:30 PM CDT
Poster Discussion Session: Saturday, June 4, 4:45 PM — 6 PM CDT
Abstract Number: 9509
Presentation Title: Mikie: A randomized, double-blinded, regimen-controlled, phase 2
study to assess the efficacy and safety of two different vismodegib
(VISMO) regimens in patients (pts) with multiple basal cell
carcinomas (BCCs)

Date/Time: Saturday, June 4, 1 PM — 4:30 PM CDT
Abstract Number: 9532
Presentation Title: Vismodegib (VISMO), a hedgehog pathway inhibitor (HPI), in
advanced basal cell carcinoma (aBCC): STEVIE study primary
analysis in 1215 patients (pts)